Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Covidien (NYSE:COV) named Stacy Enxing Seng, 47, president of its $1.4 billion global vascular therapies business. Stacy, who joined Covidien in July 2010 after the company spent $2.6 billion acquiring ev3 and its Pipeline embolization system, will lead the division’s 4,000 employees.
Boston Scientific (NYSE:BSX), stung by recent studies showing that the thinner design of next-generation stents can deform during deployment, is on the offensive with an new video.
Analysts warned against reading too much into poll results from a 1-day conference of cardiovascular leaders, in which more than half said the ongoing recall of St. Jude Medical’s (NYSE:STJ) Riata defibrillator leads is a more serious issue than Medtronic’s (NYSE:MDT) high-profile pullback of the Sprint Fidelis pacemaker lead.